PMID- 30953330
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20200518
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 36
IP  - 6
DP  - 2019 Jun
TI  - A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral 
      Rivastigmine in Patients with Mild-to-Moderate Alzheimer's Disease in Taiwan.
PG  - 1455-1464
LID - 10.1007/s12325-019-00939-0 [doi]
AB  - INTRODUCTION: Rivastigmine is a cholinesterase inhibitor, approved for the 
      treatment of mild-to-moderate dementia of Alzheimer's type. This study assessed 
      the short- and long-term effectiveness and safety of rivastigmine in patients 
      with mild-to-moderate Alzheimer's disease (AD) in a real-world clinical setting 
      in Taiwan. METHODS: This was a 48-week, single-arm, open-label, prospective, 
      observational, post-marketing surveillance, multicenter study. The primary 
      outcomes were change from baseline to week 48 in the Mini-Mental State 
      Examination (MMSE) and Clinical Dementia Rating (CDR) scores. One-year 
      persistence to treatment, effect on activities of daily living, and incidence of 
      adverse events (AEs) were also assessed. RESULTS: Overall, 151 patients were 
      enrolled in the study, of which 91 (60.26%) completed this study. At the end of 
      the study, the mean rivastigmine dose received by the patients was 6.59 mg/day. 
      At week 48, the changes in mean [standard deviation (SD)] MMSE and CDR scores in 
      the intent-to-treat (ITT) population from baseline were - 1.00 (3.8; p = 0.0344) 
      and 0.07 (0.29; p = 0.0403), respectively. The most frequently reported AEs by 
      preferred term were dizziness (12.58%) and nausea (9.27%). No new or unexpected 
      AEs were observed, and 30 (20.13%) patients in the ITT population were on 
      rivastigmine therapy for 1 year without treatment discontinuation. CONCLUSION: 
      Despite the low 1-year persistence rate, rivastigmine showed a stabilizing effect 
      on declining cognition in patients with mild-to-moderate AD in a real-world 
      scenario. Rivastigmine is well tolerated at 6.0-9.0 mg/day with no unexpected 
      safety concerns. FUNDING: Novartis Co. Ltd., Taipei, Taiwan.
FAU - Chang, Chiung-Chih
AU  - Chang CC
AD  - Department of Neurology, Cognition and Aging Center, Kaohsiung Chang Gung 
      Memorial Hospital, Chang Gung University College of Medicine, Kao-hsiung, Taiwan.
FAU - Peng, Giia-Sheun
AU  - Peng GS
AD  - Taipei Veterans General Hospital Hsinchu Branch, Hsinchu County, Taiwan.
FAU - Lai, Te-Jen
AU  - Lai TJ
AD  - Institute of Medicine and Department of Psychiatry, Chung Shan Medical University 
      Hospital, Taichung, Taiwan.
FAU - Li, Chien-Hsun
AU  - Li CH
AD  - Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, 
      Taiwan.
FAU - Liu, Ching-Kuan
AU  - Liu CK
AD  - Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, 
      Taiwan. ckliu@kmu.edu.tw.
AD  - Department of Neurology, School of Medicine, Kaohsiung Medical University, 
      Kaohsiung, Taiwan. ckliu@kmu.edu.tw.
AD  - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung, Taiwan. ckliu@kmu.edu.tw.
LA  - eng
SI  - figshare/10.6084/m9.figshare.7868804
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20190405
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Cholinesterase Inhibitors)
RN  - PKI06M3IW0 (Rivastigmine)
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*drug therapy/epidemiology
MH  - Cholinesterase Inhibitors/administration & dosage/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Research Design
MH  - Rivastigmine/administration & dosage/*therapeutic use
MH  - Taiwan/epidemiology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Cognition
OT  - Dementia
OT  - Neurology
OT  - Rivastigmine
OT  - Treatment persistence
EDAT- 2019/04/07 06:00
MHDA- 2020/05/19 06:00
CRDT- 2019/04/07 06:00
PHST- 2017/10/09 00:00 [received]
PHST- 2019/04/07 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
PHST- 2019/04/07 06:00 [entrez]
AID - 10.1007/s12325-019-00939-0 [pii]
AID - 10.1007/s12325-019-00939-0 [doi]
PST - ppublish
SO  - Adv Ther. 2019 Jun;36(6):1455-1464. doi: 10.1007/s12325-019-00939-0. Epub 2019 
      Apr 5.